RARE DISEASERESEARCH ATLAS

ORPHA:308400

Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C

high confidenceSubtype of disorder

Also known as: Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type C · MOCOD type C

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

948

85.7th percentile

Trials

0

Interventional, condition-specific

Researchers

77

Distinct authors in sample

Gene link

GPHN

Strong

Readiness

3/6

Stages with a signal

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

MOCODC · combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type C · molybdenum cofactor deficiency C · molybdenum cofactor deficiency, complementation group type C

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — GPHN

  2. LiteraturePresent

    948 matched papers (691 in last 10 years) Source

  3. Phenotype characterisedPresent

    21 HPO annotations (e.g. Hypoplasia of the pons; Reduced eye contact; Hypouricemia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (GPHN).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

21

Associated phenotypes · MONDO:0014212

  • Hypoplasia of the pons
  • Reduced eye contact
  • Hypouricemia
  • Poor head control
  • Cerebellar hypoplasia

Showing 5 of 21 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-27

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

948

948 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

948 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

691 in the last 10 years · high confidence · 85.7th percentile (publications denominator)

Phrase hits: 10 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

77

Distinct author names in 10 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Abdelhak S1 paper · 2021

    Biomedical Genomics and Oncogenetics Laboratory (LR16IPT05), Institut Pasteur de Tunis, Tunis, Tunisia.

    Papers in Europe PMC
  2. 02
    Amela I1 paper · 2018

    Departament de Bioquímica i Biologia Molecular and Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, 08193, Cerdanyola del Vallès, Barcelona, Spain.

    Papers in Europe PMC
  3. 03
    Ayyanar P1 paper · 2025

    Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND.

    Papers in Europe PMC
  4. 04
    Balanica S1 paper · 2025

    Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania.

    Papers in Europe PMC
  5. 05
    Bobeica R1 paper · 2025

    Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania.

    Papers in Europe PMC
  6. 06
    Brault J1 paper · 2021

    Department of Pediatrics, Division of Pediatric Neurology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States.

    Papers in Europe PMC
  7. 07
    Calì F1 paper · 2025

    Oasi Research Institute-IRCCS, 94018 Troina, Italy.

    Papers in Europe PMC
  8. 08
    Cedano J1 paper · 2018

    Laboratorio de Inmunología, Universidad de la República Regional Norte-Salto, Rivera 1350, 50000, Salto, Uruguay.

    Papers in Europe PMC
  9. 09
    Chouchane L1 paper · 2021

    Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.

    Papers in Europe PMC
  10. 10
    Dallali H1 paper · 2021

    Biomedical Genomics and Oncogenetics Laboratory (LR16IPT05), Institut Pasteur de Tunis, Tunis, Tunisia.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 9 September 2026 · last trial check 9 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category sulfite oxidase deficiency due to molybdenum cofactor deficiency also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: sulfite oxidase deficiency due to molybdenum cofactor deficiency

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-27

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C" OR "Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type C" OR "Combined deficiency of the sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type C" OR "MOCOD type C" OR "MOCODC" OR "molybdenum cofactor deficiency C" OR "molybdenum cofactor deficiency, complementation group type C") OR (MESH:"Molybdenum Cofactor Deficiency, Complementation Group C") OR ("GPHN" OR "GPHN syndrome" OR "GPHN-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Molybdenum Cofactor Deficiency, Complementation Group C

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C" OR "Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type C" OR "Combined deficiency of the sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type C" OR "MOCOD type C" OR "MOCODC" OR "molybdenum cofactor deficiency C" OR "molybdenum cofactor deficiency, complementation group type C" OR "Molybdenum Cofactor Deficiency, Complementation Group C"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"sulfite oxidase deficiency due to molybdenum cofactor deficiency"

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T01:47:34.914Z